Metoprolol around the time of surgery increases the risk of death and stroke: P... (s combined. Such efforts are rare but e...)

Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial

Date:5/12/2008

s combined. Such efforts are rare, but essential in order to make progress in the management of these patients, said Dr. Salim Yusuf, POISE steering committee chair, McMaster University, Hamilton, Canada.

The POISE Trial randomized 4,174 patients to receive extended-release metoprolol succinate and 4,177 patients to receive placebo starting two to four hours before surgery and continuing for 30 days after surgery.

Fewer patients in the metoprolol group (176) than in the placebo group (239) suffered a heart attack, indicating that patients receiving metoprolol were 27 percent less likely to suffer a heart attack. However, 129 metoprolol patients compared to 97 placebo patients died, indicating that patients receiving metoprolol were 33 percent more likely to die. Further, 41 metoprolol patients versus 19 placebo patients suffered a stroke, indicating that patients receiving metoprolol had more than double the risk of a stroke.

Considering the heart attacks less than one-third of these patients also had a complication of their heart attack like heart failure. In contrast more than half of the patients who suffered a stroke were left incapacitated or needing help with everyday activities.

The POISE results suggest for every 1,000 patients with a similar risk profile who have noncardiac surgery, metoprolol will prevent 15 patients from having a heart attack, three from having angioplasty or coronary artery bypass surgery, and seven from developing new atrial fibrillation (a heart rhythm disorder).

The results also suggest that for every 1,000 patients, metoprolol would cause eight patients to die, five patients to have a stroke, 53 patients to experience a low blood pressure that would require treatment, and 42 patients to experience a low heart rate that would require treatment. Analysis of the POISE data suggests that metoprolol increased the risk of death and stroke by increasing the risk of the low blood pr
'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

1

GOOD

Page: 1 2 3
Related medicine news :

1. Bicyclist to Stop in DC during 9,000 Mile Lap Around the U.S.
2. Health Organizations Join Forces Around Quit-Smoking Help
3. Bicyclist Will Conclude 9,000 Mile Lap Around the U.S. on Sunday in New York City
4. Children Around the Globe Walk Toward a Lifetime of Healthy Habits
5. Negative Publicity Around PFFS Sales Practices Not Getting Through to Seniors
6. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
7. Take a Culinary Trip Around the World for a Good Cause: March of Dimes
8. Safe Crossing Week 2007 Teaches Kids How to Behave Safely Around Trains
9. New Poll Shows Catholics Around the World Believe Good Catholics Can Use Condoms
10. Researchers From Around the World Gather to Discuss Triple Negative Breast Cancer
11. Area Around Breast Tumor May Predict Cancers Spread

Post Your Comments:

(Date:12/16/2009)... been found, , , WEDNESDAY, Dec. 16 (HealthDay News) -- ... food poisoning and the stomach pain and diarrhea that ... urinary tract infections. , Researchers have found the same ... restaurants and in women with the infections. , ... to the women through the food they ate, although ...

(Date:12/16/2009)... promote Massachusetts companies through annual marketing campaign , ... ... BioSpace unveiled the 2010 Genetown™ Hotbed Campaign as ... , ,Genetown is sponsored by MassBio and showcases ... The campaign places each entity’s brand on an electronic ...

(Date:12/16/2009)... also at all-time low, government report shows, , , WEDNESDAY, ... the United States has reached almost 78 years, a ... birth in 2007, women can expect to live to ... according to the report from the U.S. Centers for ... Americans can expect to live longer than their parents, ...

(Date:12/16/2009)... COLUMBIA, S.C., Dec. 16 Medical travel ... state-of-the-art hospitals in Puerto Rico into its network ... prices substantially lower than those at mainland U.S. ... will offer medical travel assistance and preferred pricing ... who seek treatment at either HIMA San Pablo ...

(Date:12/16/2009)... MassMutual,s Retirement Services Division has announced ... platform in Q2 2010. The new platform will ... investment change materials in a variety of themes. ... from a menu of creative options to support ... population. The new RetireSmart participant engagement platform will ...

Breaking Medicine News(10 mins):Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 2 Health News:Foodborne E. Coli Suspected in Urinary Tract Infections 3 Health News:Thriving Bioscience Region Leaves Its Mark 2 Health News: Life Expectancy in U.S. Hits New High 2 Health News: Life Expectancy in U.S. Hits New High 3 Health News:Hospitals in Puerto Rico Join Companion Global Healthcare's Network 2 Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 2 Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 3 Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 4 Health News:MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform 5

[0] Foodborne E. Coli Suspected in Urinary Tract Infections [0] Thriving Bioscience Region Leaves Its Mark [0] Life Expectancy in U.S. Hits New High [0] Hospitals in Puerto Rico Join Companion Global Healthcare's Network [0] MassMutual to Launch New RetireSmart(SM) Participant Engagement Platform

... MILLS, Md., Oct. 30 Medifast, Inc.,(NYSE: MED ) ... 2008 financial results for the period ended September 30, 2008 ... call and web,cast to discuss the results on Thursday, November ... the call by dialing (866) 524-3160 or,(412) 317-6760, or can ...

... as One of the Top 10 Most Interesting ... Oct. 30 Genaera,Corporation (NASDAQ: GENR ) ... being held November 3-5 at the Lowes Hotel ... and,Chief Scientific Officer, will provide an overview on ...

... Cardo Medical, a company engaged,in the development ... of its Align 360 Total Knee System. The ... release during the second quarter of 2009.,Cardo Medical,s ... within,its Align 360 platform which has already received ...

... 2009 Operating Preview, MELVILLE, N.Y., Oct. 30 ... a leading provider of comprehensive home,health services, today ... and 26% operating contribution growth from its Home ... clinical innovation, quality and,productivity to enhance its industry ...

... by SEIU,Secretary-Treasurer Anna Burger on Barack Obama,s prime-time special:, ... voters will head to the polls,to choose a president ... biggest economic crisis since the Great Depression., "Tonight, ... right now--tax cuts for the middle class, affordable,healthcare for ...

... and mobile devices with wireless connectivity. , ... ... a provider of clinical information for healthcare professionals, is pleased ... that delivers Lexi-Comp,s drug, disease, and formulary content on smartphones ...

Medifast, Inc. to Announce Third Quarter of Fiscal Year 2008 Financial Results on Thursday, November 6, 2008 Genaera to Present at Therapeutic Area Partnerships 2008 Cardo Medical Announces FDA Clearance of the Align 360 Total Knee System Gentiva Reports Third Quarter Revenue and Profit Growth Obama Puts Healthcare, Economic Relief for Middle Class First in Prime-Time Special Lexi-Comp Point-of-Care Information Now Available on Smartphones, Coming Soon for the iPhone™

(Date:12/16/2009)... A new application developed by American ... of specialty pharmaceuticals has increased health plan staff ... reducing costs. ,, AIM, a leading diagnostic imaging ... clients representing over 35 million consumers and an ... WLP ), adapted the successful clinical and technology ...

(Date:12/16/2009)... Technologies, Inc. (Pink Sheets: AVXT) ("AVAX" or the ... bridge loan financing (the "2009 Financing") pursuant to ... "Agreement") with Firebird Global Master Fund, Ltd., ("Firebird"). ... convertible promissory note, due June 30, 2010, in ... a warrant to purchase an aggregate of 93,333,333 ...

(Date:12/16/2009)... Dec. 16 Boston Scientific Corporation (NYSE: ... of Directors has elected Nelda Connors as a Director. ... the Electrical and Metal Products division of Tyco International. ... Corporation, holding several positions in operations and general management. ... a number of executive and management capacities with Ford, ...

Breaking Medicine Technology:American Imaging Management's New Specialty Drug Program Delivers Immediate Results 2 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 3 American Imaging Management's New Specialty Drug Program Delivers Immediate Results 4 AVAX Technologies, Inc. Closes Bridge Financing 2 AVAX Technologies, Inc. Closes Bridge Financing 3 AVAX Technologies, Inc. Closes Bridge Financing 4 Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 2 Boston Scientific Announces Election of Nelda Connors to Its Board of Directors 3 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 1 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 2 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 3 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 4 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 5 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 6 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 7 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 8 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 9 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 10 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 11 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 12 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 13 Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results 6000 14 Professor Steven Ley of University of Cambridge will Present Free Webinar 26apos 3BApplication of the ReactIR Flow Cell to Continuous Processing Tec 14728 1 Professor Steven Ley of University of Cambridge will Present Free Webinar 26apos 3BApplication of the ReactIR Flow Cell to Continuous Processing Tec 14728 2 Professor Steven Ley of University of Cambridge will Present Free Webinar 26apos 3BApplication of the ReactIR Flow Cell to Continuous Processing Tec 14728 3 COTR Refresher Course Offered 11 January 2010 28Wash DC Area 29 60727 1 COTR Refresher Course Offered 11 January 2010 28Wash DC Area 29 60727 2 COTR Refresher Course Offered 11 January 2010 28Wash DC Area 29 60727 3

[0] American Imaging Management's New Specialty Drug Program Delivers Immediate Results [0] AVAX Technologies, Inc. Closes Bridge Financing [0] Boston Scientific Announces Election of Nelda Connors to Its Board of Directors

... Aug. 21 ,Bayer HealthCare Pharmaceuticals, Inc. and ... announced the companies have begun enrolling patients,in ... the Prevention of,Recurrence of Hepatocellular Carcinoma trial. ... evaluating Nexavar(R) (sorafenib),tablets as adjuvant treatment, which ...

... Aug. 20 Enobia Pharma, an emerging biotech,company ... today announced that the first patient in its ... investigating Enzyme,Replacement Therapy (ERT) with ENB-0040 for the ... disorder for which there is no approved,treatment., ...

Other Medicine Technology:Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 2 Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 3 Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 4 Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer 5 Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 2 Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia 3

Bayer and Onyx Begin Enrollment in STORM Trial Studying Nexavar as Adjuvant Therapy for Patients With Liver Cancer Enobia Pharma Initiates Clinical Testing of Enzyme Replacement Therapy to Treat Hypophosphatasia

... the durability of natural tissue ... of ingrowth and natural adaptation ... exceeds all applicable state and ... Tissue also reduces OR time ...

Meets the demanding requirements of most pelvic floor reconstructive procedures, and is highly resistant to suture pull-through, demonstrating long-term durability, and serves as a structural support...

... The FineTech-Brindley (also known as the ... which has been used by people with ... (or urinate) on demand. A secondary use ... bowel evacuation and promote penile erection.,The Bladder ...

... Nephrostomy Balloon is used to dilate the ... nephrostomy tract during a percutaneous procedure. The ... from the balloon to the catheter shaft ... close approximation of the dilating tract to ...

Medicine Products:

FasLata® Allograft Tissue Bard Dermal Allograft FineTech-Brindley (VOCARE) Bladder System Ultraxx Nephrostomy Balloon and Set

Metoprolol around the time of surgery increases the risk of death and stroke: P...(s combined. Such efforts are rare but e...),Health